The estimated Net Worth of James A Joyce is at least $80.1 Tausend dollars as of 31 October 2018. James Joyce owns over 18,683 units of Aethlon Medical Inc stock worth over $80,063 and over the last 10 years James sold AEMD stock worth over $0.
Sign up
James Joyce AEMD stock SEC Form 4 insiders trading
James has made over 8 trades of the Aethlon Medical Inc stock since 2017, according to the Form 4 filled with the SEC. Most recently James exercised 18,683 units of AEMD stock worth $19,430 on 31 October 2018.
The largest trade James's ever made was exercising 98,107 units of Aethlon Medical Inc stock on 7 February 2017 worth over $419,898. On average, James trades about 19,038 units every 53 days since 2014. As of 31 October 2018 James still owns at least 212,370 units of Aethlon Medical Inc stock.
You can see the complete history of James Joyce stock trades at the bottom of the page.
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
What's James Joyce's mailing address?
James's mailing address filed with the SEC is 9635 GRANITE RIDGE DRIVE, SUITE 100, , SAN DIEGO, CA, 92123.
Insiders trading at Aethlon Medical Inc
Over the last 11 years, insiders at Aethlon Medical Inc have traded over $56,658 worth of Aethlon Medical Inc stock. The most active insiders traders include James A Joyce, Angela Rossetti und Chetan Shah. On average, Aethlon Medical Inc executives and independent directors trade stock every 56 days with the average trade being worth of $4,427. The most recent stock trade was executed by Chetan Shah on 17 December 2020, trading 26,852 units of AEMD stock currently worth $56,658.
What does Aethlon Medical Inc do?
the aethlon medical (nasdaq:aemd) mission is to create innovative devices that address unmet medical needs in cancer, infectious disease, and other life-threatening conditions. our aethlon adapt™ platform provides the technology foundation for a new class of therapeutics that target the selective removal of disease enabling particles from the entire circulatory system. the aethlon adapt™ product pipeline includes the hemopurifier®, a first-in-class medical device with broad-spectrum capabilities against exosomes that contribute to the progression of cancer and infectious viral pathogens such as hiv and hepatitis c.
What does Aethlon Medical Inc's logo look like?
Complete history of James Joyce stock trades at Aethlon Medical Inc
Aethlon Medical Inc executives and stock owners
Aethlon Medical Inc executives and other stock owners filed with the SEC include:
-
Steven P. Larosa M.D.,
Chief Medical Officer & Acting Chief Scientific Officer -
Dr. Charles J. Fisher Jr., M.D.,
CEO, Director & Member of Extracorporeal Therapy Advisory Board -
James B. Frakes M.B.A.,
CFO, Sr. VP of Fin. & Sec. -
James Frakes,
Chief Financial Officer, Senior Vice President - Finance, Secretary -
Charles Fisher,
Chief Executive Officer -
Guy F. Cipriani BS (Eng.), MBA,
Sr. VP, Chief Bus. Officer & Director -
Chetan Shah,
Independent Director -
Sabrina Johnson,
Independent Director -
Guy Cipriani,
Independent Director -
Edward Broenniman,
Chairman of the Board -
Dr. Richard H. Tullis,
Consultant -
Sunil Sawhney,
Head of Clinical Studies -
Rodney S Kenley,
President -
Timothy C Jr Rodell,
Chief Executive Officer -
Franklyn S Jr Barry,
Director -
Richard Tullis,
VP, CHIEF SCIENCE OFFICER -
Phillip A Ward,
Director -
James A Joyce,
Chairman, CEO, Secretary -
Nicolas Gikakis,
-
Steven P Larosa,
Chief Medical Officer -
Angela Rossetti,
-
Lee D Arnold,
Chief Scientific Officer